JTT 130

Drug Profile

JTT 130

Alternative Names: JTT-130

Latest Information Update: 01 May 2012

Price : $50

At a glance

  • Originator Japan Tobacco
  • Developer Akros Pharma; Japan Tobacco
  • Class Antihyperlipidaemics
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 26 Apr 2012 Discontinued - Phase-II for Type-2 diabetes mellitus in Russia (PO)
  • 26 Apr 2012 Discontinued - Phase-II for Type-2 diabetes mellitus in Netherlands (PO)
  • 26 Apr 2012 Discontinued - Phase-II for Type-2 diabetes mellitus in Hungary (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top